bleomycin + vincristine + methotrexate + prednisone

This is a combination chemotherapy regimen consisting of four cytotoxic agents—bleomycin, vincristine, methotrexate, and prednisone. Each drug has a distinct mechanism of action: - **Bleomycin** is an antitumor antibiotic that induces DNA strand breaks. - **Vincristine** is a vinca alkaloid that inhibits microtubule formation in mitosis. - **Methotrexate** is an antimetabolite and antifolate agent that inhibits dihydrofolate reductase, blocking DNA synthesis. - **Prednisone** is a synthetic glucocorticoid with lympholytic effects. This combination has been used in various investigational regimens for the treatment of lymphomas and other cancers. While not as widely established as named protocols like MACOP-B or BACOP (which include additional agents), this four-drug combination has been studied for its potential efficacy in hematologic malignancies and metastatic cancers[6]. The regimen leverages multiple mechanisms to target rapidly dividing cancer cells.